Redefining Intelligent
Medicine for Inflammation & Pain
(NYSE: APUS)
Apimeds is redefining intelligent medicine—where clinical judgment, scientific rigor, and human insight guide every decision. We are advancing a non-narcotic therapeutic for high-need conditions, Apitox, a novel agent derived from purified honey bee venom.
Apimeds US is publicly traded on the New York Stock Exchange (Ticker: APUS) and led by a team of experienced biopharma professionals committed to delivering meaningful healthcare advancements. We are actively pursuing licensing and acquisition opportunities to grow our pipeline and expand our impact.
Sign Up for Updates | Get the Fact Sheet
Key Reasons to Watch
NYSE: APUS
Confirmatory Phase 3 planned; prior Phase 3 showed clinically significant pain & function improvements.
Used in South Korea since 2003; >810,000 doses across >1,200 facilities reported with no serious adverse events by sponsor.
$13.5M IPO completed (May 2025); management states current cash supports planned confirmatory Phase 3.
Upcoming trial in MS pain—single-site study planned; large unmet need with no current approved drugs.
Mission-led team applying clinical judgment and real-world expertise (ai²™)
Subscribe for investor updates — we’ll send you the latest deck
Our Mission
Advancing healthcare via critical thinkers and dedicated scientists in order to provide the healthcare community advancements that improve quality of life allowing patients to believe in Apimeds as a source of hope and delivering physicians a vehicle for advancing the science of treatment.
Company Snapshot
Apimeds Pharmaceuticals (APUS)
Apimeds is a clinical-stage biopharmaceutical company advancing Apitox, a first-in-class, intradermally administered biologic derived from purified honeybee venom. The company is pursuing FDA approval for Apitox in knee osteoarthritis, supported by compelling Phase 3 efficacy data and a 20-year safety history from use in South Korea.
With a bold mission to improve lives through actual intelligence (ai²™)—human insight, cross-disciplinary thinking, and clinical judgment—Apimeds is building a next-generation model for drug development. Publicly traded on NYSE American, the company is also preparing a study in MS-related pain, addressing an urgent and underserved market.
Our Values
Dedicated to Patients
Real needs, real lives-our therapies begin there.
Science with Integrity
We follow the data—openly, ethically, always.
Visionary Growth
Ambition backed by strategy. Growth powered by vision.
Collaborative Excellence
We build smarter, faster—together.
Agility in Action
We move fast, think sharp, and act with purpose.
Investment Insights
What Investors Are Watching
Clinically Proven Biologic
Apitox showed significant pain and function improvement in a Phase 3 trial across all OA grades.
Massive Market Need
32M+ U.S. adults have OA. Current treatments (NSAIDs, opioids) have major risks or poor efficacy.
De-Risked Platform
Apitox has been used in >800,000 doses in Korea with no serious adverse events reported.
Pipeline Expansion in MS Pain
No approved drugs exist. Apitox’s anti-inflammatory and neuroprotective properties offer promise.
12 Years of Market Exclusivity
If approved, Apitox qualifies for 12 years of U.S. biologic exclusivity under FDA rules.
Market Opportunity
Poised to Capitalize on a Multi-Billion Dollar Opportunity
Osteoarthritis Market Surge
The U.S. OA treatment market is projected to grow from $8.2B (2022) to $20.2B (2032). Apitox offers a novel, non-opioid solution.
Unmet MS Pain Need
Millions suffer from MS-related pain—yet no drugs are approved. Apitox is entering this whitespace.
Biologic Edge with Broad Utility
As a purified bee venom biologic, Apitox may also benefit other inflammatory and autoimmune conditions.
Smart, Cost-Efficient Strategy
Lean trials, focused programs, and targeted indications create a highly scalable development model.
ai²™ Drives Competitive
Advantage
Apimeds leverages “actual intelligence”—human clinical judgment, not just algorithms—to evaluate and execute.
We believe Apitox has the potential to reshape how we manage chronic pain—safely, naturally, and intelligently.
– Erik Emerson, CEO, Apimeds Pharmaceuticals
Apitox is investigational and not approved by the FDA.
©2025 Apimeds Pharmaceuticals. All Rights Reserved | Privacy Policy | Legal Disclaimer